TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery
TELA Bio (NASDAQ: TELA) has announced the U.S. commercial launch of larger sizes of OviTex® PRS Reinforced Tissue Matrix for plastic and reconstructive surgery. The expanded portfolio now includes a 25 x 30 cm oval and a 25 cm diameter circle, offering larger options than any human acellular dermal matrix product currently available.
The company reports significant growth with OviTex PRS, having sold nearly 15,000 units since its 2019 launch, achieving 31% year-over-year unit sales growth in 2024. The larger configurations aim to reduce the need for multiple smaller pieces during complex procedures, potentially improving surgical efficiency and reducing costs.
TELA Bio (NASDAQ: TELA) ha annunciato il lancio commerciale negli Stati Uniti di dimensioni maggiori di OviTex® PRS Reinforced Tissue Matrix per la chirurgia plastica e ricostruttiva. Il portafoglio ampliato include ora un ovale di 25 x 30 cm e un cerchio di 25 cm di diametro, offrendo opzioni più grandi rispetto a qualsiasi prodotto di matrice dermica acellulare umana attualmente disponibile.
L'azienda riporta una crescita significativa con OviTex PRS, avendo venduto quasi 15.000 unità dal suo lancio nel 2019, raggiungendo un incremento delle vendite unità del 31% anno su anno nel 2024. Le configurazioni più grandi mirano a ridurre la necessità di più pezzi più piccoli durante procedure complesse, migliorando potenzialmente l'efficienza chirurgica e riducendo i costi.
TELA Bio (NASDAQ: TELA) ha anunciado el lanzamiento comercial en EE. UU. de tamaños más grandes de OviTex® PRS Reinforced Tissue Matrix para cirugía plástica y reconstructiva. La cartera ampliada ahora incluye un óvalo de 25 x 30 cm y un círculo de 25 cm de diámetro, ofreciendo opciones más grandes que cualquier producto de matriz dérmica acelular humana actualmente disponible.
La compañía informa un crecimiento significativo con OviTex PRS, habiendo vendido casi 15,000 unidades desde su lanzamiento en 2019, logrando un crecimiento del 31% en las ventas unitarias interanuales en 2024. Las configuraciones más grandes tienen como objetivo reducir la necesidad de múltiples piezas más pequeñas durante procedimientos complejos, lo que podría mejorar la eficiencia quirúrgica y reducir costos.
TELA Bio (NASDAQ: TELA)는 미국에서 플라스틱 및 재건 수술을 위한 OviTex® PRS 강화 조직 매트릭스의 더 큰 사이즈 상업 출시를 발표했습니다. 확장된 포트폴리오는 현재 25 x 30 cm 타원형과 25 cm 직경의 원형을 포함하여 현재 사용 가능한 모든 인체 비세포성 피부 매트릭스 제품보다 더 큰 옵션을 제공합니다.
회사는 OviTex PRS와 함께 상당한 성장을 보고하며, 2019년 출시 이후 거의 15,000개 유닛을 판매하였고, 2024년에는 전년 대비 31%의 유닛 판매 성장률을 달성했습니다. 더 큰 구성은 복잡한 절차 중 여러 개의 작은 조각이 필요할 수 있는 상황을 줄이는 것을 목표로 하여, 수술 효율성을 개선하고 비용을 절감할 수 있습니다.
TELA Bio (NASDAQ: TELA) a annoncé le lancement commercial aux États-Unis de tailles plus grandes d'OviTex® PRS Matrice Tissulaire Renforcée pour la chirurgie plastique et reconstructive. Le portefeuille élargi comprend désormais un ovale de 25 x 30 cm et un cercle de 25 cm de diamètre, offrant des options plus grandes que tout produit de matrice dermique acellulaire humain actuellement disponible.
L'entreprise rapporte une croissance significative avec OviTex PRS, ayant vendu près de 15 000 unités depuis son lancement en 2019, atteignant une croissance des ventes unitaires de 31 % d'une année sur l'autre en 2024. Les configurations plus grandes visent à réduire le besoin de plusieurs pièces plus petites lors de procédures complexes, ce qui pourrait améliorer l'efficacité chirurgicale et réduire les coûts.
TELA Bio (NASDAQ: TELA) hat den kommerziellen Launch größerer Größen von OviTex® PRS Verstärktem Gewebe-Matrix für plastische und rekonstruktive Chirurgie in den USA angekündigt. Das erweiterte Portfolio umfasst nun ein ovales Format von 25 x 30 cm und einen Kreis mit einem Durchmesser von 25 cm, was größere Optionen bietet als jedes derzeit verfügbare menschliche acelluläre Dermisprodukt.
Das Unternehmen berichtet von einem signifikanten Wachstum mit OviTex PRS und hat seit dem Launch im Jahr 2019 fast 15.000 Einheiten verkauft, mit einem Wachstum der Einheitverkäufe von 31% im Jahresvergleich für 2024. Die größeren Konfigurationen sollen die Notwendigkeit mehrerer kleiner Teile während komplexer Eingriffe reduzieren, was potenziell die chirurgische Effizienz verbessert und Kosten senkt.
- 31% year-over-year unit sales growth in 2024 for OviTex PRS
- Sold nearly 15,000 units since 2019 launch
- Product portfolio expansion with larger sizes than competitors
- Potential cost reduction through simplified surgical procedures
- None.
Insights
TELA Bio's launch of larger OviTex PRS sizes represents a strategic product expansion that strengthens their competitive positioning in the plastic and reconstructive surgery market. The new 25 x 30 cm oval and 25 cm diameter circle configurations give TELA a distinct advantage by offering sizes larger than any competing human acellular dermal matrix product.
The 31% year-over-year unit sales growth in 2024 and cumulative sales of nearly 15,000 units since the 2019 product launch demonstrate significant commercial traction for this product line. For a company with a
This expansion directly addresses an efficiency gap in complex reconstructive procedures by potentially eliminating the need to suture multiple smaller matrices together. This value proposition resonates with both clinical and economic stakeholders in hospitals and surgery centers who are focused on procedural efficiency and cost reduction.
The company's reference to surgeons "increasingly seeking alternatives to cadaveric tissue" indicates TELA is capitalizing on a market shift away from traditional materials. By expanding their product line to include these larger configurations, TELA is positioning itself to capture additional market share in complex reconstructive cases where larger reinforcement materials are required.
For investors, this expansion represents a logical evolution of an already successful product line rather than an entirely new market entry, suggesting a lower-risk pathway to incremental revenue growth.
The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market
MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic and reconstructive surgery.
Designed for consistency in thickness, stretch, permeability, and handling while facilitating functional remodeling,1 the OviTex PRS portfolio now includes expanded size offerings, including a 25 x 30 cm oval and a 25 cm diameter circle. These larger configurations may reduce the need for multiple smaller pieces and have the potential to simplify more complex plastic and reconstructive procedures.
“The introduction of larger OviTex PRS sizes aligns with evolving trends in plastic and reconstructive surgery and strengthens the breadth of our offering in this space,” said Antony Koblish, Co-founder, President & CEO. “Since launching OviTex PRS in 2019 we have sold nearly 15,000 units, with year-over-year unit sales growth of
“These new sizes directly address the needs expressed by our key opinion leaders and customers,” emphasized Dr. Howard Langstein, Vice President of Medical Affairs & Surgeon Strategy. “By reducing the need for suturing multiple smaller pieces together, we aim to improve surgical efficiency and potentially reduce costs, enhancing the surgeon’s ability to reinforce larger soft-tissue challenges.”
To learn more, visit ovitexprs.com.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
About OviTex PRS Devices
OviTex PRS is for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. The device is supplied sterile and is intended for one-time use.
For important safety information, refer to the IFU.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management, including with respect to the launch of larger sizes of TELA’s OviTex PRS Reinforced Tissue Matrix. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business from macroeconomic conditions, including recessionary concerns, banking instability, increasing market interest rates, monetary policy changes, changes in trade policies, including tariffs, and inflationary pressures, potentially impacting our ability to market our products; demand for our products related to changes in volumes or frequency of surgical procedures, including due to outbreak of illness or disease, cybersecurity events impacting hospital operations, labor and hospital staffing shortages, supply chain disruptions to critical surgical and hospital supplies, pricing pressures or any other applicable adverse healthcare economic factors; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance our product offerings; product development and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement for procedures using our products; and product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
Media Contact
Lisa Novy-Wikowski
484-354-6782
lnovywikowski@telabio.com
- Overbeck N, Beierschmitt A, May BCH, Qi S, Koch J. In-vivo evaluation of a reinforced ovine biologic for plastic and reconstructive procedures in a non-human primate model of soft tissue repair. ePlasty. 2022;22:e43. – Preclinical test results may not necessarily be indicative of human clinical performance.
FAQ
What are the new sizes of TELA Bio's OviTex PRS product launch?
How many OviTex PRS units has TELA Bio sold since its 2019 launch?
What was TELA Bio's OviTex PRS unit sales growth in 2024?
What advantages do the new larger OviTex PRS sizes offer for surgical procedures?
How does TELA Bio's new OviTex PRS size compare to competitors?
